COUGHLIN DUFFY LLP
350 Mount Kemble Avenue
P.O. Box 1917
Morristown, New Jersey 07962-1917
(973) 267-0058
Attorneys for Defendants AstraZeneca Pharmaceuticals LP,

FILED

APR 0 4 2008

Judge Jamie D. Happas

ELLENIDE ADCONI

AstraZeneca LP, Astra USA, Inc., KBI Sub Inc., and Zeneca Inc.

ELLEN PEARSON,

SUPERIOR COURT OF NEW JERSEY LAW DIVISION: MIDDLESEX COUNTY

Plaintiff,

DOCKET NO. MID-L-317-07-MT

v.

CIVIL ACTION

ASTRAZENECA
PHARMACEUTICALS LP, et al.,

In Re Risperdal/Seroquel/Zyprexa Litigation

Case No. 274

Defendants.

ORDER OF DISMISSAL WITH PREJUDICE

RETURN DATE: April 4, 2008

THIS MATTER having been brought before the Court by Coughlin Duffy LLP, attorneys for Defendants AstraZeneca Pharmaceuticals LP, AstraZeneca LP, Astra USA, Inc., KBI Sub Inc., and Zeneca Inc. (collectively "AstraZeneca") to dismiss plaintiff's Complaint with prejudice for failure to provide an executed Acknowledgment and/or executed authorizations with the Short Form Plaintiff Fact Sheet ("Short Form PFS") pursuant to Case Management Order No. 4 ("CMO 4"), §§ II.B. and II.C; the Court having entered an Order of Dismissal without prejudice, dated December 19, 2007, that expressly authorizes a dismissal with prejudice in the event plaintiff fails to vacate that Order of Dismissal without prejudice on or before March 16, 2008; and plaintiff having failed to provide an executed Acknowledgment and/or executed authorizations with the Short Form PFS and having failed to vacate the Order of Dismissal without prejudice on or before March 16, 2008; and for good cause shown;

IT IS on this 4th day of April , 2008;

ORDERED that AstraZeneca's motion is hereby GRANTED, and that plaintiff's Complaint is DISMISSED with prejudice against all parties – served and unserved; and it is further

ORDERED that a signed copy of this Order be served on all counsel of record within seven (7) days of the date hereof.

Jamie D. Happas, J.S.C.

Unopposed Opposed

Having reviewed the above motion, I find it to be meritorious on its face and is unopposed. Pursuant to R.1:6-2, it therefore will be granted essentially for the reasons set forth in the moving papers.